Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$5.05 USD
+0.06 (1.20%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.02 -0.03 (-0.59%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Capricor Therapeutics (CAPR) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$20.00 | $40.00 | $8.00 | 300.80% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Capricor Therapeutics comes to $20.00. The forecasts range from a low of $8.00 to a high of $40.00. The average price target represents an increase of 300.8% from the last closing price of $4.99.
Analyst Price Targets (5 )
Broker Rating
Capricor Therapeutics currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/20/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Strong Buy | Strong Buy |
9/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/23/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
7/2/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $20.00 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 63 of 253 |
Current Quarter EPS Est: | -0.34 |
CAPR FAQs
Capricor Therapeutics, Inc. (CAPR) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for Capricor Therapeutics, Inc. (CAPR) is $20.00. The current on short-term price targets is based on 4 reports.
The forecasts for Capricor Therapeutics, Inc. (CAPR) range from a low of $8 to a high of $40. The average price target represents a increase of $296.04 from the last closing price of $5.05.
The current UPSIDE for Capricor Therapeutics, Inc. (CAPR) is 296.04%
Based on short-term price targets offered by five analysts, the average price target for Capricor Therapeutics comes to $20.00. The forecasts range from a low of $8.00 to a high of $40.00. The average price target represents an increase of 300.8% from the last closing price of $4.99.